Trade ELVN stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Enliven Therapeutics, Inc. (ELVN) is trading at US$45.59, down 2.95% today as of Oct 5, 11:40 EDT. The company has a market capitalisation of US$4.38B. Over the past 52 weeks, ELVN has traded between US$14.79 and US$62.32. On Syfe you can trade ELVN with $0 commission and add it to your watchlist.
| Previous close | US$46.97 |
|---|---|
| Market cap | US$4.38B |
| 52-week range | US$14.79 – US$62.32 |
| Volume | 1.12M |
| Exchange | US |
Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. Its pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002. The company was founded by Samuel S. Kintz, Joseph P. Lyssikatos, and Anish Patel on June 1, 2019 and is headquartered in Boulder, CO.
Year: 2023
William Blair Initiates Enliven Therapeutics at Outperform
Aug 18, 11:01 AM · MT Newswires
Enliven Therapeutics, Inc. (ELVN) stock is trading at US$45.59, -2.95% from the previous close of US$46.97.
The market cap for Enliven Therapeutics, Inc. (ELVN) stock is approximately US$4.38B.
The 52-week high for Enliven Therapeutics, Inc. (ELVN) stock is US$62.32.
The 52-week low for Enliven Therapeutics, Inc. (ELVN) stock is US$14.79.
Enliven Therapeutics, Inc. (ELVN) does not currently pay a dividend.
Stay on top of ELVN
Price moves, news and earnings — straight to your inbox.
Snapshot
Popular Stocks in Singapore
